Micah Zajic
Keine laufenden Positionen mehr
Karriereverlauf von Micah Zajic
Ehemalige bekannte Positionen von Micah Zajic
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| LEXEO THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.01.2023 | 01.07.2023 |
| Corporate Officer/Principal | 01.07.2023 | 31.12.2023 | |
| SQZ BIOTECHNOLOGIES COMPANY | Finanzdirektor/CFO | 11.07.2022 | 31.12.2022 |
| Corporate Officer/Principal | 16.09.2020 | 11.07.2022 | |
MeiraGTx Ltd.
 MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01.04.2017 | 01.09.2020 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.04.2014 | 01.04.2017 |
Ausbildung von Micah Zajic
| Georgetown University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| Vereinigtes Königreich | 2 |
Operativ
| Corporate Officer/Principal | 4 |
| Director of Finance/CFO | 2 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| LEXEO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
MeiraGTx Ltd.
MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- Micah Zajic
- Erfahrung
